Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on INT 1. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102264672A details a scalable route to chiral phenols using Ru-catalyzed transfer hydrogenation, offering cost reduction and high purity for pharmaceutical manufacturing.
Patent CN119638592A discloses a novel route for semaglutide side chain. Achieve high purity and reduced emulsification risks for scalable GLP-1 manufacturing.
Patent CN114478290A reveals a metal halide catalyzed route for oseltamivir intermediates, offering superior purity and yield without column chromatography for reliable supply chains.
Patent CN102382053B details a novel route for tolvaptan intermediate offering higher yield and purity for reliable pharmaceutical intermediates supplier operations.
Novel asymmetric hydrogenation route for moxifloxacin intermediates eliminates chiral resolution waste, offering high ee values and scalable production for global API manufacturers.
Patent CN105273025A reveals novel N-formyl protection for Cangrelor intermediates. Enhances purity and simplifies purification for reliable pharmaceutical supply chains.
Advanced chiral preparation method for Carfilzomib intermediate ensuring high purity and yield. Optimized for commercial scale-up and cost reduction in pharmaceutical intermediates manufacturing.
Novel purification process for Pentazocine intermediate 113-C ensuring high purity and supply reliability for pharmaceutical manufacturing partners globally.
Novel patent CN114805218B offers eco-friendly rosuvastatin intermediate synthesis. Reduces aluminum waste and avoids expensive DIBAL-H for reliable supply.
Patent CN114805218B reveals a novel synthesis route for Rosuvastatin Calcium Intermediate, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN113444702B reveals high-efficiency OYE1 mutant for Brivaracetam intermediate production, offering superior conversion and ee values for scalable API manufacturing.
Patent CN114181132A reveals a novel high-purity synthesis route for nintedanib intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Novel three-step synthesis for Rimegepant intermediate offers high yield and safety. Ideal for reliable pharmaceutical intermediates supplier partnerships.
Patent CN109503462B details a novel synthesis for Tofacitinib intermediates, offering improved stereoselectivity and cost reduction in API manufacturing through optimized catalytic hydrogenation.
This novel ruthenium catalyst method ensures high dr value and cost reduction in pharmaceutical intermediates manufacturing for reliable supply chain partners globally.
Patent CN111018734B reveals a cost-effective route for cinacalcet intermediates using Meldrum's acid, offering reliable supply chain solutions and reduced manufacturing costs for global pharma.
Novel patent CN120774805A route for irinotecan intermediates. Higher yield, simplified steps, reliable pharmaceutical intermediate supplier for global scale-up.
Novel copper-catalyzed route for Lamellarin intermediates offers high yield and cost efficiency for pharmaceutical manufacturing supply chains globally ensuring stability and purity standards.
Patent CN103694162A reveals a mild synthesis for Levomilnacipran intermediates. Discover cost-effective routes avoiding de-ethylation impurities for reliable supply chain integration.
Discover the novel 4-step synthesis of Montelukast Sodium intermediate via patent CN115710221A. Achieve high purity, reduced costs, and scalable supply chain solutions.